|
2025
|
Invention
|
Composition containing human urine concentrate, method for producing same, cell population, human... |
|
2024
|
Invention
|
Antisense nucleic acids.
The present invention provides a pharmaceutical agent which causes skip... |
|
|
Invention
|
Antisense nucleic acids.
Provided is a drug that allows highly efficient skipping of exon 51 in ... |
|
|
Invention
|
Antitumor agent, screening method for antitumor agent, and prognosis test drug. An antitumor agen... |
|
|
Invention
|
Neuroprotective agent. Provided are: a novel compound that is useful for the treatment of disease... |
|
|
Invention
|
Method for assisting diagnosis of secondary progressive multiple sclerosis, and method for screen... |
|
|
Invention
|
Antisense nucleic acids.
Provided is a drug that allows highly-efficient skipping of exon. The p... |
|
|
Invention
|
Antisense nucleic acids.
The present invention provides a pharmaceutical composition which cause... |
|
|
Invention
|
Cell population of human urine-derived cells, and cell population of myotubes induced therefrom a... |
|
|
Invention
|
Antisense nucleic acids.
The present invention provides an oligomer which allows exon 45 skippin... |
|
|
Invention
|
Composition for treating central nervous system injury. This composition for treating central ner... |
|
|
Invention
|
Composition for treating central nervous system injury. A composition for treating central nervou... |
|
2023
|
Invention
|
Anti-human cx3cr1 antibody. The present invention addresses the problem of providing, inter alia,... |
|
|
Invention
|
Multiple sclerosis diagnostic method and diagnostic biomarker. A multiple sclerosis diagnostic me... |
|
|
Invention
|
Agent for preventing aftereffects of viral infection. The purpose of the prevent invention is to ... |
|
|
Invention
|
Method for predicting and evaluating therapeutic effect in diseases related to il-6 and neutrophi... |
|
|
Invention
|
Preventive agent, disease progression inhibitor, or therapeutic agent for central demyelinating d... |
|
|
Invention
|
Stem cells for transplantation and manufacturing method therefor.
It is intended to provide MSCs... |
|
2022
|
Invention
|
Antisense nucleic acids.
The present invention provides an oligomer which efficiently enables to... |
|
|
Invention
|
Opioid receptor antagonist and pharmaceutical composition. Provided are an opioid receptor antago... |
|
|
Invention
|
Antisense nucleic acid inducing skipping of exon 51. The present specification provides a drug th... |
|
|
Invention
|
Combination of antisense oligomers.
Herein, a combination of antisense oligomers or pharmaceutic... |
|
|
Invention
|
Combination of antisense oligomers. In the present description, provided is a combination of anti... |
|
|
Invention
|
Antisense nucleic acid that induces skipping of exon 50. The present specification provides a dru... |
|
|
Invention
|
Therapeutic agent for autoimmune diseases. The present invention provides a polypeptide having an... |
|
2021
|
Invention
|
Myelin sheath repair agent. The present invention provides an agent for the treatment or preventi... |
|
|
Invention
|
Discrimination method for determining depressive state, and depressive state determination system... |
|
|
Invention
|
Assessment method for determination of being in depressed state, and depressed state determinatio... |
|
|
Invention
|
Drug delivery particle and method for producing the same.
An object of the present invention is ... |
|
|
Invention
|
Antisense nucleic acids. Provided is a drug that allows highly-efficient skipping of exon. The pr... |
|
|
Invention
|
Antisense nucleic acids.
Provided is a drug that allows highly-efficient skipping of exon 51 in ... |
|
|
Invention
|
Mutant of adeno-associated virus (aav) capsid protein.
The present invention provides: a mutant ... |
|
|
Invention
|
Antisense nucleic acid inducing skipping of exon 51.
The present specification provides a drug t... |
|
|
Invention
|
Antisense nucleic acid inducing skipping of exon 51. Provided is a drug that allows efficient ski... |
|
|
Invention
|
Antisense nucleic acids. The present invention provides an oligomer which efficiently enables to ... |
|
|
Invention
|
Prophylactic agent, onset-suppressing agent or therapeutic agent for progressive immune demyelina... |
|
2020
|
Invention
|
Antisense nucleic acid that induces skipping of exon 50.
The present specification provides a dr... |
|
|
Invention
|
Antisense nucleic acid that induces skipping of exon 50. The present description provides a drug ... |
|
|
Invention
|
Antisense nucleic acid enabling exon skipping.
The present specification provides an antisense o... |
|
|
Invention
|
Antisense nucleic acid enabling exon skipping. In the present description, provided are an antise... |
|
|
Invention
|
Antisense nucleic acids. The present invention provides an oligomer which allows exon 45 skipping... |
|
|
Invention
|
Therapeutic agent for progressive disease caused by increase in eomes-positive cd4-positive t cel... |
|
|
Invention
|
Nucleic acid delivery complex.
Provided are a complex that comprises a nucleic acid-containing n... |
|
2019
|
Invention
|
Biomarker for myalgic encephalomyelitis/chronic fatigue syndrome (me/cfs).
A method for diagnosi... |
|
2018
|
Invention
|
Method for inducing muscular cells using cells in spot urine.
A method for preparing myotubes in... |
